Market Overview

J.P. Morgan Reiterates Neutral Rating on Bristol Myers Squibb Co.

Share:
Related BMY
AbbVie And Bristol-Myers Squibb Strike Oncology Clinical Alliance To Assess Rova-T plus Opdivo And Opdivo + Yervoy Regimen
Bristol-Myers Squibb Gets CHMP's Positive Opinion For ORENCIA
Bristol-Myers and Janssen Biotech team up in lung cancer (Seeking Alpha)

In a report published Monday, J.P. Morgan & Co. reiterated its Neutral rating on Bristol Myers Squibb Co. (NYSE: BMY).

J.P. Morgan noted, “Maintain Neutral rating. We continue to view pipeline progression as the key driver for BMY shares and see a number of important events in 2013 including the launch of Eliquis, longer-term data on the company's PD-1 program as well as CV outcomes data for Onglyza. That said, we believe current valuation adequately reflects this with the stock trading at 18x trough 2013E EPS and remain Neutral on BMY shares.”

Bristol Myers Squibb Co. closed on Friday at $31.90.

Latest Ratings for BMY

DateFirmActionFromTo
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold
May 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!